Stock ONVO ORGANOVO HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Organovo Holdings, Inc.

Equities

ONVO

US68620A2033

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
0.924 USD -6.30% Intraday chart for Organovo Holdings, Inc. -10.29% -16.76%
04-15 Organovo's fatty liver disease drug meets main goal in mid-stage study RE
04-15 Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
AQ
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
AQ
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
AQ
Organovo: Fiscal Q3 Earnings Snapshot
AQ
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
AQ
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
AQ
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
AQ
Organovo: Fiscal Q2 Earnings Snapshot
AQ
Organovo Highlights FXR314 Combination Therapy Potential and Plan
AQ
Organovo : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
Organovo to Participate in the H.C. Wainwright Global Investment Conference
AQ
Organovo : Change in Certifying Accountants - Form 8-K
PU
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
AQ
Organovo : Costs Associated with Exit/Disposal - Form 8-K
PU
Organovo Announces FXR Program
GL
ORGANOVO HOLDINGS, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
ORGANOVO HOLDINGS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates
GL
ORGANOVO HOLDINGS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
ORGANOVO HOLDINGS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONVO Stock
  4. News Organovo Holdings, Inc.
  5. Press Releases